Osimertinib Mesylate (CAS 1421373-66-1)

Application and positioning

Osimertinib mesylate is a third-generation, irreversible EGFR tyrosine kinase inhibitor active against both activating EGFR mutations and the T790M resistance mutation, supplied as the mesylate salt. It is used in oral tablets for EGFR-mutant non-small cell lung cancer, in the first-line setting and in T790M-positive patients. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Ponatinib Hydrochloride (CAS 1114544-31-8)
• Poziotinib (CAS 1092364-38-9)
• Regorafenib Hydrate (CAS 1019206-88-2)
• Ribociclib Succinate (CAS 1374639-75-4)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.